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with colorectal cancer: a case control study
Cenk K Pusatcioglu1, Elizabeta Nemeth2, Giamila Fantuzzi3, Xavier Llor4, Sally Freels5, Lisa Tussing-Humphreys6,
Robert J Cabay7, Rose Linzmeier2, Damond Ng2, Julia Clark4 and Carol Braunschweig3*Abstract
Background: Increased cellular iron exposure is associated with colorectal cancer (CRC) risk. Hepcidin, a liver
peptide hormone, acts as the primary regulator of systemic iron status by blocking iron release from enterocytes
into plasma. Concentrations are decreased during low iron status and increased during inflammation. The role of
hepcidin and the factors influencing its regulation in CRC remains largely unknown. This study explored systemic
and tumor level iron regulation in men with CRC.
Methods: The participants were 20 CRC cases and 20 healthy control subjects. Colonic tissue (adenocarcinoma
[cases] healthy mucosa [controls]) was subjected to quantitative PCR (hepcidin, iron transporters and IL-6) and Perls’
iron staining. Serum was analyzed using ELISA for hepcidin, iron status (sTfR) and inflammatory markers (CRP, IL-6,
TNF-α). Anthropometrics, dietary iron intake and medical history were obtained.
Results: Cases and controls were similar in demographics, medication use and dietary iron intake. Systemically,
cases compared to controls had lower iron status (sTfR: 21.6 vs 11.8 nmol/L, p < 0.05) and higher marker of
inflammation (CRP: 8.3 vs 3.4 μg/mL, p < 0.05). Serum hepcidin was mildly decreased in cases compared to controls;
however, it was within the normal range for both groups. Within colonic tissue, 30% of cases (6/20) presented iron
accumulation compared to 5% of controls (1/20) (χ2 = 5.0; p < 0.05) and higher marker of inflammation (IL-6: 9.4-fold
higher compared to controls, p < 0.05). Presence of adenocarcinoma iron accumulation was associated with higher
serum hepcidin (iron accumulation group 80.8 vs iron absence group 22.0 ng/mL, p < 0.05).
Conclusions: While CRC subjects had serum hepcidin concentrations in the normal range, it was higher given their
degree of iron restriction. Inappropriately elevated serum hepcidin may reduce duodenal iron absorption and
further increase colonic adenocarcinoma iron exposure. Future clinical studies need to assess the appropriateness of
dietary iron intake or iron supplementation in patients with CRC.
Keywords: Iron metabolism, Hepcidin, Inflammation, Anemia, Colorectal cancerBackground
Excessive body iron levels are associated with increased
risk for colorectal cancer (CRC) [1-6]. This is due to the
high oxidative potential of iron which can result in the
formation of reactive oxygen species and mutate the DNA
of key genes involved in cell proliferation [2]. Additionally,
since iron is required for cell proliferation, increased iron
levels could contribute to tumor promotion [1].* Correspondence: braunsch@uic.edu
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1919 W Taylor St, Chicago, IL 60612, USA
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article, unless otherwise stated.Iron levels and its tissue distribution in the body are
regulated by hepcidin, a hepatic-derived systemic iron
regulatory hormone [7-9]. Hepcidin is increased by in-
flammation and decreased by iron insufficiency and
erythropoiesis [10-12]. Mechanistically, hepcidin con-
trols iron release into plasma by degrading the iron ex-
porter ferroportin (FPN) in cells that handle iron,
including intestinal enterocytes, hepatocytes, and mac-
rophages [13]. Thus, when concentrations of hepcidin
are elevated, FPN expression is low, resulting in reduced
dietary iron absorption and impaired mobilization from
stores.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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FPN in cancer [14,15]. Serum hepcidin levels were found
to be elevated in some hematologic or nonhematologic
cancers, likely because of the presence of inflammation,
but the pathophysiological relevance of these findings is
unknown [16,17]. For FPN, it was reported that patients
with breast cancer had decreased tumor expression of
FPN protein compared to non-involved tissue, and that
tumor FPN mRNA levels were negatively correlated with
advanced staging [14]. This suggested that iron retention
by breast cancer cells may affect cancer progression.
Hepcidin may be elevated in persons with CRC due to
cancer-induced inflammation [18,19]. However, because
CRC patients frequently have anemia or low iron status,
hepcidin levels may also be decreased [20,21]. Evaluation
of the involvement of hepcidin in regulating systemic
and tumor level iron metabolism in CRC is limited to
one study [15]. Ward et al. reported that systemic hepci-
din is elevated with advanced cancer staging [15]. Addition-
ally, they demonstrated that mRNA expression of hepcidin
is detected within a subset (34%) of colonic tumors com-
pared to healthy non-involved mucosa. In a complemen-
tary study by Brookes et al., increases in iron acquisition
proteins (Divalent metal transporter-1, DMT-1; Transfer-
rin receptor-1, TfR1) and decreases in proteins related to
cellular iron efflux (FPN; Hephaestin, Heph) were noted
in colonic tumors when compared to non-involved mu-
cosa [1]. The authors suggested that these alterations in
iron transport may explain the iron sequestration com-
monly observed in colonic tumors [1]. What remains un-
known is hepcidin’s role in regulating colonocyte iron
transport and whether it contributes to tumor iron accu-
mulation in persons with CRC.
The purpose of this study was to examine simultan-
eously systemic and tumor iron status and their regulation
in men with CRC compared to controls. This was assessed
by measuring: (i) hepcidin, iron status and markers of in-
flammation in serum and (ii) hepcidin, expression of iron
transporters (DMT-1, FPN), inflammation and iron accu-
mulation in colonic mucosa. We hypothesized that CRC
would be associated with higher levels of hepcidin in
serum and tumor compared to controls and that hepcidin
levels would be correlated with markers of inflammation
and mucosal iron accumulation.
Methods
Ethics
All subjects signed an informed consent and the study
procedures were approved by the University of Illinois at
Chicago Institutional Review Board.
Study population and characteristics
Study subjects were recruited from patients scheduled
for colonoscopies due to abdominal pain, bloating, changein bowel movements or for CRC screening at the University
of Illinois at Chicago and John H. Stroger Jr. Cook County
Hospital between May 2011 and June 2012. “Cases” were
classified as newly diagnosed CRC with adenocarcinoma
based on pathology reports for their tumor biopsies; “con-
trols” were selected from the subjects with healthy colonic
mucosa (absence of adenomatous polyps or GI abnormal-
ities). Cases and controls (n = 20/group) were matched to
have a similar difference within each pair for age (within
5 years), body mass index (BMI) (within 4 units) and waist
circumference (within 5 cm). Due to gender-specific vari-
ation in reference ranges for iron parameters, participation
was restricted to males. Additional exclusions included
medical conditions that could affect iron status such as
gastrointestinal bleeding, hemochromatosis, history of in-
flammatory bowel disease or infection.
Following informed consent, questionnaires for basic
demographic information, health history, medication and
supplement use and alcohol consumption were adminis-
tered by a research team member. The Block Brief 2000
food frequency questionnaire (FFQ) was used to assess
usual dietary intake over the previous 12 months [22].
Height was measured with a stadiometer to nearest
0.1 cm and weight using a balance beam scale to nearest
0.1 kilograms with subjects wearing a hospital gown.
Waist circumference was measured with a flexible tape
(AccuFitness, Greenwood Village, CO) at the midpoint
between the ribs and iliac crest, to the nearest 0.1 cm.
Body mass index was calculated as weight in kilograms
divided by height in meters squared. CRC staging (0-IV)
based on tumor size, lymph nodes affected and metasta-
sis (TNM) was classified using the American Joint Com-
mittee on Cancer (AJCC) criteria [23].Laboratory assays
All blood samples were collected after a minimum 12 hour
fast following the endoscopy or prior to surgical inter-
vention. A separate analysis did not reveal any differences
in serum parameters by blood collection type. Colonic
adenocarcinoma tissue was obtained from cases at the
time of surgical resection. Healthy colonic mucosa from
the descending colon in the controls was obtained using
standard sized biopsy forceps during colonoscopy.Serum parameters
Systemic iron regulation was assessed by serum hepcidin
and iron status by serum transferrin receptor (sTfR),
which primarily reflects erythroid iron demand. Serum
transferrin receptor is not influenced by acute or chronic
inflammation and can help differentiate between iron-
related disorders [24]. Elevated sTfR is indicative of
iron-deficient erythropoiesis [25]. Anemia was exam-
ined by hemoglobin (Hb). Inflammation was evaluated
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(IL-6) and tumor necrosis factor-alpha (TNF-α).
Serum hepcidin was measured by competitive enzyme-
linked immunosorbent assay (c-ELISA) (Intrinsic LifeSciences,
La Jolla, CA). For healthy men with normal iron status,
the range for this assay is 29–254 ng/mL [8]. Serum
transferrin receptor was measured using the Quantikine
IVD Human sTfR Immunoassay ELISA (R&D Systems,
Minneapolis, MN; normal reference range 8.7-28.1 nmol/L).
Hemoglobin was obtained from the medical chart and
anemia was defined as <12 g/dL [21]. CRP, IL-6 and TNF-α
were measured using R&D Systems Quantikine ELISA kits
(R&D Systems, Minneapolis, MN).
Tissue specimen
A portion of colonic tissue was placed in formalin and
paraffin-embedded for histological analysis. The remaining
portion of the colonic tissue was placed in RNAlater
(Ambion, Austin, TX) and stored at −80°C for gene expres-
sion (mRNA) analysis.
Real time polymerase chain reaction (RT-PCR)
Total RNA was extracted from colonic mucosa sections
using the Maxwell 16 System (Promega, Fitchburg, WI).
The complementary DNA was synthesized from the RNA
using iScript™ cDNA Synthesis Kit (BioRad, Hercules, CA).
Gene expression (mRNA) of divalent metal transporter-1
(DMT-1), ferroportin (FPN), hepcidin and IL-6 were mea-
sured quantitatively by RT-PCR (For primers used see
Additional file 1) using SsoAdvanced SYBR Green Super-
mix (BioRad). Amplifications were performed at 57°C for
40 cycles using the C1000 Touch (BioRad) and data ana-
lyzed using the CFX Manager software (BioRad). Results
were normalized to reference genes Glyceraldehyde 3-
phosphate dehydrogenase (GADPH) and β-actin to obtain
ΔCt values (ΔCt = Ct[reference] - Ct[target]). As both
GADPH and β-actin showed equivalent results, we used
the average of the two values for the final representation.
Fold change in mRNA expression in cases compared to
controls was calculated using 2ΔΔCt, where ΔΔCt = average
ΔCt for cases - average ΔCt for controls. Statistical com-
parison was performed using raw ΔCt values (Additional
file 2).
Iron staining
Tissue iron accumulation was measured qualitatively by
Perls’ Prussian blue staining. The tissue section was
treated with dilute hydrochloric acid to release ferric
ions from binding proteins. These ions then reacted with
potassium ferrocyanide to produce an insoluble blue
compound (the Prussian blue reaction). The grading of
iron staining was performed by a pathologist blinded to
the experimental group and reported dichotomously as
presence or absence of iron accumulation (+/−).Statistical analysis
Prior to analysis, all variables were assessed for normality
and presence of outliers. Descriptive statistics included
mean, standard deviation (SD), median and interquartile
range (IQR) for continuous variables and frequencies for
categorical variables. Difference between cases and controls
was assessed by student’s paired t-test or non-parametric
Wilcoxon signed-rank test for continuous variables and
McNemar’s test for categorical variables. Non-parametric
Spearman’s Rank correlation coefficient was used to explore
bivariate relationships. Multivariable linear regression was
performed to adjust for confounders. All analyses were
performed using SAS version 9.3 (Cary, North Carolina).
P-values were two-sided and the statistical significance
level was defined as p < 0.05.
Results
Subject characteristics are presented in Table 1. By de-
sign cases and controls were similar in age, BMI and
waist circumference. Race/ethnicity, dietary iron intake
(heme and non-heme food and supplemental sources),
medication use and alcohol consumption were also simi-
lar between cases and controls.
Systemic iron regulation and inflammation
Systemic iron status and inflammatory parameters are
presented in Table 2. Cases had significantly lower Hb
and higher sTfR compared to controls (p < 0.05), indica-
tive of iron-restricted erythropoiesis. Serum hepcidin
was mildly decreased in cases, likely as a response to the
increased erythroid iron demand (as reflected by the ele-
vated sTfR). However, considering that hepcidin con-
centrations were still in the normal range for cases,
hepcidin may be elevated given their degree of iron re-
striction. Hepcidin is known to be low or undetectable
in individuals with insufficient iron status [8]. Cases also
had significantly elevated CRP (p < 0.05) and a trend to-
ward increased IL-6 concentrations compared to con-
trols, indicating the presence of mild inflammation in
these patients. This may stimulate hepcidin production
and counterbalance the suppressive effect of iron-restricted
erythropoiesis on hepcidin.
Associations between serum hepcidin and iron status
and inflammatory parameters were explored with Spearman
correlation coefficients. In controls, serum hepcidin was
correlated with Hb (r = 0.54; p = 0.01) as expected, and
no associations were found with sTfR or inflammatory
markers (CRP, IL-6, TNF-α), which were in the normal
range. In cases, serum hepcidin was not correlated with
any of the parameters (Hb, sTfR or the inflammatory
markers). Additionally, cancer staging did not change
serum hepcidin concentrations (Stage IV: median 64.4
(IQR 249.1) versus Stage I: 72.8 (IQR 28.7) ng/mL p = 1.0).
Since our lab previously demonstrated that obesity-induced
Table 1 Subject characteristics between cases and
controls
Cases
(n = 20)
Controls
(n = 20)
P-value*
Age 61.0 (8.0) 57.5 (12.0) 0.25
BMI 25.7 (5.0) 26.9 (7.3) 0.38
WC(cm) 100.4 (11.5) 103.3 (18.2) 0.49
Race (%)
African American 50% 75% 0.16
White 30% 5%
Hispanic 5% 10%
Asian 15% 10%
Dietary iron (grams/day)
Heme 6.7 (4.3) 7.0 (4.3) 0.99
Non-heme 0.67 (0.7) 0.66 (0.64) 0.99
Alcohol (grams/day) 0.23 (2.0) 1.0 (2.1) 0.46
Medications use (yes)
Aspirin 40% 65% 0.16
NSAIDs 50% 40% 0.53
COX-2 inhibitors 10% 5% 0.56
Cancer staging†
I 15%
II 40%
III 30%
IV 15%
Values shown as median (IQR), or percentage.
*p-value of difference between cases and controls using Wilcoxon signed-rank
test or McNemar’s test as appropriate.
†American Joint Committee on Cancer (AJCC) criteria.
BMI, body mass index; WC, waist circumference.
Table 2 Iron status and markers of inflammation in
serum between cases and controls
Cases
(n = 20)
Controls
(n = 20)
P-value*
Hb (g/dL)† 11.7 (2.9) 13.2 (1.3) 0.01
sTfR (nmol/L)† 21.6 (17.0) 11.8 (6.1) 0.01
Hepcidin (ng/mL)† 58.6 (62.1) 96.0 (34.1) 0.10
CRP (μg/mL) 8.3 (3.4) 3.4 (4.7) 0.002
IL-6 (pg/mL) 2.7 (2.2) 1.9 (1.3) 0.06
TNF-α (pg/mL) 0.32 (0.27) 0.24 (0.36) 0.62
Values shown as median (IQR).
*p-value of difference between cases and controls using Wilcoxon
signed-rank test.
†Reference range for healthy men [9]. Hb, 13.5-17.5 g/dL; sTfR, 8.7-28.1 ng/mL;
Hepcidin, 29–254 ng/mL.
Hb, hemoglobin; sTfR, serum transferrin receptor; CRP, c-reactive protein;
IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha.
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levels, we stratified cases and controls by obesity status
(obese ≥ 102 cm, lean < 102 cm) [26,27]. Within cases, cir-
culating markers of inflammation and serum hepcidin did
not differ by obesity status (data not shown). Obese con-
trols were more inflamed (CRP, IL-6) compared to lean;
however, serum hepcidin concentrations were similar be-
tween the groups.
Iron transporters in colonic mucosa
Gene expression (mRNA) of hepcidin, iron transporters
(DMT-1 and FPN) and the pro-inflammatory protein IL-
6 in colonic mucosa are presented in Table 3. Expression
of DMT-1 and FPN were similar between cases and con-
trols. Although cases had a 2.9-fold lower expression of
hepcidin compared to controls (p < 0.05), overall both
groups expressed very low hepcidin mRNA in the co-
lonic mucosa (close to the limit of detection by qPCR).
Cases had a 9.4-fold higher expression of IL-6 compared
to controls (p < 0.05), confirming the inflammatory na-
ture of the tumor. Correlation analyses did not reveal
significant associations between expression of the serum
and colonic markers of iron regulation, iron transport or
inflammation in cases or controls (data not shown).
Iron accumulation in colonic mucosa
To determine if CRC was associated with greater tissue
iron accumulation, adenocarcinoma from cases and healthy
colonic mucosa from controls was examined using Perls’
Prussian blue stain. Iron accumulation was present in more
cases than controls (n = 6/20; 30%; n = 1/20; 5%, χ2 = 5.00;
p < 0.05). Illustrative Perls’ stains are shown in Figure 1
(cases A-B, controls C-D). When cases were dichotomized
by presence/absence of iron accumulation (+/−), cases
with iron accumulation had higher serum hepcidin com-
pared to the cases without iron accumulation (p < 0.05)
(Table 4). However, after adjusting for Hb, differences in
serum hepcidin between these subgroups became non-
significant. This suggests that systemic iron sufficiency
may have contributed to the higher serum hepcidin ob-
served in the iron accumulation (+) group given thatTable 3 mRNA expression of iron transporters and
inflammatory proteins in colonic tissue of colorectal
cancer cases and controls using 2ΔΔCt conversion
Cases
(n = 20)
Controls
(n = 20)
P-value*
DMT-1 1.12 1.0 0.59
FPN 0.81 1.0 0.59
Hepcidin 0.35 1.0 0.001
IL-6 9.38 1.0 0.0002
Values shown as relative expression in cases compared to controls, i.e. reference.
*p-value of difference between cases and controls using student’s paired t-test.
DMT-1, divalent metal transporter-1; FPN, ferroportin; IL-6, interleukin-6.
Figure 1 Iron staining in colonic tissue between cases and controls. Sections of colonic tissue (adenocarcinoma for cases, healthy mucosa
for controls) were tested for presence of iron accumulation using the Perls’ Prussian blue staining. Cases with presence (A) and absence (B) of
iron accumulation were compared to controls with presence (C) and absence of iron accumulation (D) and presented as 20X magnification.
There was more iron accumulation detected in cases than controls (n = 6/20; 30%; n = 1/20; 5%; McNemar’s test: χ2 = 5.0; p < 0.05).
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support, there was a trend for lower sTfR in the iron (+)
group, demonstrating iron bioavailability. Differences in
systemic inflammatory markers (CRP, IL-6 or TNF-α)
between cases with different iron accumulation (+/−)
were non-significant. Additionally, no differences wereTable 4 Iron status and markers of inflammation in
serum between cases with colonic iron presence (+) and
without iron presence (−)
Iron (+) Iron (−) P-value* P-value†
(n = 6) (n = 14)
Hb (g/dL) 12.8 (2.0) 11.2 (3.4) 0.20 -
sTfR (nmol/L) 11.0 (14.3) 22.2 (18.0) 0.11 0.32
Hepcidin (ng/mL) 80.8 (28.6) 22.0 (48.4) 0.02 0.12
CRP (μg/mL) 7.7 (3.4) 7.9 (3.4) 0.43 0.31
IL-6 (pg/mL) 2.5 (3.0) 2.7 (2.0) 0.99 0.86
TNF-α (pg/mL) 0.27 (0.3) 0.38 (0.3) 0.46 0.41
Values shown as median (IQR).
*p-value of difference between iron(+) and iron (−) using non-parametric
Mann–Whitney U test.
†p-value of difference between iron(+) and iron (−) adjusting for Hb with
multiple linear regression.
Hb, hemoglobin; sTfR, serum transferrin receptor; CRP, c-reactive protein;
IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha.observed for tissue level (mRNA expression for DMT-1,
FPN, hepcidin, IL-6) parameters or with cancer staging
(data not shown).Discussion
Individuals with CRC frequently have anemia or low iron
status which may, at least in part, be due to an inflamma-
tory response termed the anemia of chronic disease
(ACD) [18,20,21,28,29]. The ACD is thought to manifest
through increased hepatic production of the iron regula-
tory protein hepcidin, which can down-regulate the iron
exporter FPN [10,13,30]. Reduction of FPN limits iron
flow into circulation from both the diet and storage sites
and promotes tissue iron sequestration. Beyond impaired
iron status and red blood cell production, the ACD may
be relevant for persons with CRC given that hepcidin-
induced reductions in dietary iron absorption in the
proximal gut may increase colonic iron exposure. Colonic
tumors may benefit from this alteration since iron is a
substrate for cell proliferation, cancer progression and me-
tastasis [1,2,5,6]. The primary aims of this case–control
study were to simultaneously examine systemic and tumor
level iron status and regulation in men with CRC com-
pared to controls and determine if systemic or tumor level
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accumulation.
We found cases had significantly more iron-restricted
erythropoiesis based on Hb and sTfR compared to con-
trols. We could not differentiate whether this mild anemia
was due to inflammation or also to frank iron deficiency.
Often, gastrointestinal bleeding can contribute to iron
deficiency in CRC; however, we excluded persons with
known gastrointestinal bleeding, suggesting other fac-
tors contributed to the iron restriction observed in cases
[29,31]. Typically when iron deficiency is present, serum
hepcidin concentrations are undetectable [8]. Indeed,
cases had lower serum hepcidin compared to controls;
however, this difference was not significant and was
within the normal range. This suggests hepcidin levels
were inappropriately elevated given the patients’ iron-
restricted erythropoiesis. Hepcidin expression is simul-
taneously regulated by inflammation, iron stores and
erythropoiesis [7,10]. Further, hepcidin levels are ultim-
ately determined by the relative strength of these oppos-
ing stimuli [12,32]. In contrast to controls where serum
hepcidin was correlated with Hb, serum hepcidin within
cases was not significantly correlated with Hb suggest-
ing that multiple signals may be influencing its produc-
tion. Significantly greater systemic and colonic mucosal
inflammation was observed in cases compared to con-
trols which may have provided the necessary stimuli to
promote increased hepatic hepcidin production, despite
elevated sTfR and low iron status. This phenotype, in
which serum hepcidin is simultaneously regulated by
low iron status and inflammation, has been previously
reported in morbid obesity [26,33,34]. Similar to our cases,
obese participants in these studies presented with low iron
status, elevated systemic inflammation and serum hepci-
din concentrations within the normal range [26]. Like
obesity, the iron profile observed in our cases is consistent
with a mixed anemia for which hallmarks of the ACD and
iron deficiency coexist [9]. This phenotype allows for the
mobilization of iron from body stores but impairs iron re-
pletion as a result of reduced dietary iron absorption [35].
Therefore, over time, inflammation-induced chronically
elevated hepcidin would precipitate cellular iron depletion
as body iron losses exceed dietary absorption effort
[27,36]. Importantly, this type of mixed anemia has the
potential to increase gastrointestinal iron exposure in
persons with CRC.
We assessed colonic mucosal iron transport and regula-
tion and found no statistical difference in expression of
DMT-1 or FPN between cases and controls. Directionally
our DMT-1 and FPN expression were similar to those of
Brookes et al. [1]. They reported increased colonocyte ex-
pression of iron influx (DMT-1) and decreased iron efflux
(FPN) proteins in CRC compared to controls. This sug-
gests that CRC tissue is associated with greater colonicadenocarcinoma iron uptake and sequestration compared
to healthy mucosa. We observed very low hepcidin ex-
pression in the colonic tumors and healthy mucosa. This
is not unexpected given that hepcidin is primarily pro-
duced in hepatocytes. In our previous analysis, abdominal
subcutaneous and visceral adipose tissue also expressed
very low mRNA expression compared to the liver [26].
Very little is known regarding the role of extra-hepatic
hepcidin in systemic and tissue-level iron regulation. Our
findings indicate that colonic hepcidin has a minimal role
in tumor iron regulation. Ward et al. reported elevated
tumor hepcidin expression within 34% of cases compared
to non-involved healthy mucosa; however, other factors
that regulate hepcidin expression including inflammation,
iron status and dietary iron intake were not examined,
limiting interpretations of their findings [15]. Given that
few studies have examined the role of extra-hepatic hep-
cidin in regulating systemic or tissue-level iron metabol-
ism, further investigations are warranted to understand
mechanisms related to iron metabolism in colonic tu-
mors [15,37-39].
We observed significantly more cases (30%) had detect-
able iron accumulation compared to controls (5%). Perls’
staining has relatively low sensitivity. We speculate iron
accumulation would have been much more prevalent in
cases had we used a more sensitive assessment method.
Brookes et al. used DAB-enhanced Perls’ methodology
and detected visible iron accumulation in all (n = 20) of
the CRC cases but not controls [1]. To further characterize
the cases with iron accumulation, we examined systemic
hepcidin and iron status parameters. The iron (+) group
had elevated serum hepcidin compared to cases without
iron accumulation. However, the iron (+) group was also
more iron sufficient and had higher Hb. Given the small
sample of cases with iron accumulation, it is hard to make
any definitive conclusions. However, our data coupled
with the report by Brookes et al. suggests that a subset of
persons with CRC have increased expression of systemic
hepcidin, which may precipitate greater intestinal iron ex-
posure, and promote tumor iron retention [1]. In a murine
model of CRC, animals had increased tumor growth when
fed a high iron diet compared to a low iron diet [5]. Also,
in persons with ulcerative colitis (UC), who have co-
existing systemic and colonic inflammation and hepcidin-
mediated dietary iron malabsorption, luminal iron expos-
ure is associated with greater colonic inflammation and
mucosal proliferation [40-42]. Therefore, studies examin-
ing the effect of dietary iron restriction in persons with
CRC should be explored.
The link with hepcidin and excess tumor iron accumu-
lation provides further evidence for its role in cancer.
Only one other study has comprehensively explored the
hepcidin-FPN axis and its relationship in cancer pro-
gression. Pinnix et al. using human breast cancer tissue
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enable rapid cell proliferation [14]. Unfortunately, the
authors did not measure systemic hepcidin concentra-
tions and future exploration should focus on its role in
tumor iron retention in other epithelial cancers.
Our study had strengths and limitations. A significant
strength was that we simultaneously measured hepcidin
systemically and in colonic mucosa while accounting for
several factors that can contribute to hepcidin regulation,
including iron status, inflammation and dietary iron in-
take. Additionally, we included a metabolically healthy
control group. However, this study had limitations, includ-
ing a relatively small sample size. Therefore, when we
stratified by presence of iron accumulation in the CRC
cases, this may have reduced the statistical power to detect
differences. Tissue analysis with adenocarcinoma in cases
to healthy mucosa in a control group was not a direct com-
parison. Future studies should also include non-involved
mucosa in cases to accurately describe our analysis among
all groups. Due to limited tissue allocated for this study,
we were unable to accurately measure protein expression
of the colonic iron exporter via FPN. Ferroportin is post-
translationally modified by hepcidin, which may have pre-
cluded us from observing a significant correlation between
colonic FPN and hepcidin. Although we suggest dietary
iron absorption may be impaired in persons with CRC,
we did not examine dietary iron absorption in this study.
Finally, our design included only males, thus generalizability
to females may be limited.
Conclusion
In summary, our study demonstrates for the first time that
CRC in some men is associated with a mixed anemia
pathology characterized by iron restricted erythropoiesis.
We believe the simultaneous presence of inflammation
(increases hepcidin) and iron insufficiency (suppresses
hepcidin) in a subset of our men with CRC resulted in
hepcidin concentrations inappropriately elevated given their
depleted iron status. Further, these findings suggest that
systemic hepcidin in some CRC cases may 1) decrease duo-
denal iron absorption resulting in low iron status and 2)
contribute to excess colonic iron exposure and disease
promotion. Given the high incidence of CRC and the ac-
companying low iron status, these findings could have sig-
nificant clinical implications [21,43]. Future investigations
into the risks and benefits of dietary iron intake and oral
iron supplementation in persons with CRC are warranted.
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